
Enzyme Replacement in Pancreatic Cancer: What Pharmacists Should Know
Key Takeaways
- Pancreatic ductal adenocarcinoma and prior pancreatic surgery confer high EPI risk, and targeted stool-history questions uncover steatorrhea patients may not spontaneously report.
- Initial PERT dosing is 48,000–72,000 lipase units per meal and about half with snacks, split between the start and middle of eating and titrated to fat content.
A new US consensus on pancreatic enzyme replacement therapy in pancreatic cancer highlights how pharmacists can counsel patients on taking enzymes with food, check response early, and address barriers to filling the prescription.
Weight loss and loose stools in a patient with pancreatic cancer can look like familiar effects of treatment. When a patient also describes greasy stools or bloating after meals, those symptoms warrant a conversation about exocrine pancreatic insufficiency (EPI). In EPI, too few digestive enzymes reach the intestine, impairing digestion and putting patients at risk for malnutrition. Pancreatic enzyme replacement therapy (PERT) treats that deficiency, but patients need to take the enzymes with the food they are meant to help digest.1,2
On World Pancreatic Cancer Day, November 19, a recent US multidisciplinary consensus in The Oncologist offers guidance on prescribing PERT and helping patients use it. The authors combined a literature review and focus groups with a modified Delphi process involving 17 experts. Agreement ranged from 94% to 100% for the 6 statements highlighted in the paper, which cover areas such as dosing, patient education, follow-up, and access. Comparative outcomes across dosing strategies remain an open question.1,3
Recognize the Symptoms Patients May Leave Out
Pancreatic ductal adenocarcinoma and prior pancreatic surgery both place patients at high risk for EPI. Patients may report diarrhea without mentioning that their stools float, look oily, or are difficult to flush. Asking what has changed about their stools and whether they are losing weight can help pharmacists identify symptoms to relay to the oncology team. The American Gastroenterological Association identifies fecal elastase, measured on a solid or semisolid stool sample, as the preferred initial test. Patients can continue taking prescribed enzymes during testing.2,4
Tie the Prescription to How the Patient Eats
The pancreatic cancer consensus recommends a starting range of 48,000 to 72,000 lipase units with a meal and approximately half the meal dose with a snack or small meal. The panel advises dividing the meal dose between the start and middle of the meal and adjusting for meal size and fat content. At dispensing, pharmacists can translate the prescribed lipase units into the number of capsules the patient should take with a meal or snack. A patient who eats small portions throughout the day may also need to clarify how a nutrition shake fits into that plan.1,4
Counseling should follow the instructions for the product dispensed. The prescribing information for pancrelipase delayed-release capsules (Creon), for example, directs patients to swallow the capsules whole and avoid crushing or chewing the contents. If a patient has trouble swallowing, pharmacists can review the product’s instructions for opening the capsule and taking the contents with a soft, acidic food. The label also directs against substituting another pancreatic enzyme product for Creon, so a formulary change warrants coordination with the prescriber.5
Follow Up on Symptoms and Access
The consensus recommends reassessment within 1 to 2 weeks of starting PERT and again if symptoms develop or worsen. The American Gastroenterological Association identifies less steatorrhea and improvement in weight or nutritional measures as signs of response. At an early follow-up, asking a patient to walk through yesterday’s meals and enzyme doses can reveal a missed snack dose or capsules taken after a meal. If symptoms persist despite use as prescribed, the pharmacist can relay the patient’s dosing history and weight trend to the oncology team and dietitian so they can reassess the regimen and consider other causes.1,2
Before assessing response, confirm that the patient was able to fill the prescription. The consensus asks teams to consider out-of-pocket cost and capsule burden when prescribing PERT. If a copay delays pickup, the pharmacist can check the plan’s preferred product and connect eligible patients with financial assistance. If the patient is struggling with the number of capsules at each meal, the pharmacist can ask the prescriber whether a higher capsule strength would deliver the prescribed lipase dose with fewer capsules. A follow-up call can then establish whether the patient has the enzymes in hand and can explain how they will take them with their next meal.1
REFERENCES
1. Gallagher D, Yaceczko S, Kitagawa M, et al. Pancreatic enzyme replacement therapy in pancreatic cancer: first U.S. consensus highlights on dosing, management, and provider inertia. Oncologist. 2026;31(12):oyag389. doi:10.1093/oncolo/oyag389
2. Whitcomb DC, Buchner AM, Forsmark CE. AGA clinical practice update on the epidemiology, evaluation, and management of exocrine pancreatic insufficiency: expert review. Gastroenterology. 2023;165(5):1292-1301. doi:10.1053/j.gastro.2023.07.007
3. World Pancreatic Cancer Day 2026. World Pancreatic Cancer Coalition. Accessed November 19, 2026.https://www.worldpancreaticcancercoalition.org/world-pancreatic-cancer-day-2026/
4. Pancreatic enzymes. Pancreatic Cancer Action Network. Accessed November 19, 2026. what-to-know-about-pancreatic-enzymes
5. Creon. Prescribing information. AbbVie Inc; 2024. Accessed November 19, 2026. https://www.rxabbvie.com/pdf/creon_pi.pdf
Related to this article








